中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 8
Aug.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(8): 1778-1781

Targeting functional cure of hepatitis B and establishing a China-specific evaluation benchmark for novel hepatitis B drugs: Interpretation of Q&A Document for the technical guidance for clinical trials of therapeutic drugs for chronic hepatitis B virus infection

DOI: 10.12449/JCH260807
  • 1.

    Department of Infectious Diseases，Nanfang Hospital，Southern Medical University，Guangzhou 510515，China

  • 2.

    Department of Hepatology，Center of Infectious Diseases and Pathogen Biology，The First Hospital of Jilin University，Changchun 130061，China

Research funding:

National Science and Technology Major Project (2025ZD1803701)

More Information
  • Corresponding author: Hou Jinlin， jlhousmu@163.com （ORCID： 0000-0001-8230-8583）
  • Received Date: 2026-07-08
  • Accepted Date: 2026-07-20
  • Published Date: 2026-08-25
    Abstract
  • Achieving the functional cure （clinical cure） of hepatitis B is the primary goal of current clinical hepatology and novel drug research and development. In 2023， the Center for Drug Evaluation， National Medical Products Administration， issued Technical guidance for clinical trials of therapeutic drugs for chronic hepatitis B virus infection to establish a top-level regulatory framework. Supporting Q&A documents for public consultation were released in July 2026 to provide practical policy guidance for the research and development of novel hepatitis B drugs， which has far-reaching implications for clinical investigators， innovative pharmaceutical enterprises， and the development of hepatology.

     

    • FullText(HTML)
  • loading
    • References(8)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Chin J Clin Infect Dis, 2022, 15( 6): 401- 427. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.001.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022, 15( 6): 401- 427. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.001.
    [2]
    You H, Maiwall R, Chen J, et al. APASL clinical practice guidelines on the management of chronic hepatitis B infection: A 2026 update[J]. Hepatol Int, 2026. DOI: 10.1007/s12072-026-11108-1.[ Epub ahead of print]
    [3]
    Center for Drug Evaluation, National Medical Products Administration. Technical guidance for clinical trials of therapeutic drugs for chronic hepatitis B virus infection[EB/OL].( 2023-04-25)[ 2026-07-16]. https://www.cde.org.cn/main/att/download/dcb4a9d069bffa935f7481f35139509b. https://www.cde.org.cn/main/att/download/dcb4a9d069bffa935f7481f35139509b

    国家药品监督管理局药品审评中心. 慢性乙型肝炎病毒感染治疗药物临床试验技术指导原则[EB/OL].( 2023-04-25)[ 2026-07-16]. https://www.cde.org.cn/main/att/download/dcb4a9d069bffa935f7481f35139509b. https://www.cde.org.cn/main/att/download/dcb4a9d069bffa935f7481f35139509b
    [4]
    Center for Drug Evaluation, National Medical Products Administration. Q&A Document for the technical guidance for clinical trials of therapeutic drugs for chronic hepatitis B virus infection[EB/OL].( 2026-07-06)[ 2026-07-16]. https://www.cde.org.cn/main/att/download/b5c643fc45ce555042ba839e8d94c10f. https://www.cde.org.cn/main/att/download/b5c643fc45ce555042ba839e8d94c10f

    国家药品监督管理局药品审评中心.《慢性乙型肝炎病毒感染治疗药物临床试验技术指导原则》问答文件[EB/OL].( 2026-07-06)[ 2026-07-16]. https://www.cde.org.cn/main/att/download/b5c643fc45ce555042ba839e8d94c10f. https://www.cde.org.cn/main/att/download/b5c643fc45ce555042ba839e8d94c10f
    [5]
    Hou J L, Lim S G, Buti M, et al. Phase 3 results of bepirovirsen treatment for chronic hepatitis B virus infection[J]. N Engl J Med, 2026, 394( 24): 2395- 2406. DOI: 10.1056/NEJMoa2515131.
    [6]
    Hou J L, Zhang W H, Xie Q, et al. Xalnesiran with or without an immunomodulator in chronic hepatitis B[J]. N Engl J Med, 2024, 391( 22): 2098- 2109. DOI: 10.1056/NEJMoa2405485.
    [7]
    Fanning G C, Zoulim F, Hou J L, et al. Therapeutic strategies for hepatitis B virus infection: Towards a cure[J]. Nat Rev Drug Discov, 2019, 18( 11): 827- 844. DOI: 10.1038/s41573-019-0037-0.
    [8]
    Ghany M G, Buti M, Lampertico P, et al. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference[J]. J Hepatol, 2023, 79( 5): 1254- 1269. DOI: 10.1016/j.jhep.2023.06.002.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (10) PDF downloads(0) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return